When Politics Hijack NIH Grant Review, Science Risks Get Lost

In late July the Office of Management and Budget floated a rule that would make it mandatory for political appointees to give the final thumbs‑up on every NIH grant. The language is blunt: projects must “demonstrably advance the President’s policy priorities” and must not “facilitate” any effort that could be seen as promoting “anti‑American values.” In other words, if a grant no longer aligns with the administration’s wishes, it can be pulled.

The comment period closed on July 13 and, although the OMB still has to finish the rule‑making by the end of August, the damage to the research ecosystem may already be underway. Reporters and scholars have rightly warned that turning grantmaking into a political exercise will erode merit‑based funding, intimidate scientists, and even drive talent out of the United States.

Those are serious concerns, but they’re only part of the story. A less obvious, yet equally troubling, risk is that the NIH will lose its quietly powerful role as a regulator of scientific risk‑taking. Since the 1950s the agency has acted as a kind of first‑responder, working side‑by‑side with researchers to shape policies on everything from human‑subject protection to bio‑security.

Take the institutional review board, or IRB, system that now underpins virtually every federally funded study involving people. Most people assume Congress or the FDA birthed that framework, but it was actually the NIH that invented it. In the 1950s the institute needed a way to handle ethical dilemmas arising from its own volunteer studies, so it asked grantees to set up local review committees. Those committees proved so useful that the FDA later adopted the model and Congress eventually codified it.

A similar story played out with laboratory safety. When genetic engineering tools first emerged in the 1970s, the NIH voluntarily drafted biosafety guidelines and tied compliance to funding. Those rules, enforced by local oversight groups, became the de‑facto standard. When the 2000s brought tighter federal oversight of the most dangerous pathogens, regulators simply borrowed the NIH playbook instead of reinventing the wheel.

Both examples hinge on a collaborative relationship: scientists see the NIH as a partner, not a police force, and the agency respects the expertise of the research community. If the new rule turns NIH leadership into a political puppet, that partnership frays. Researchers will be less inclined to bring forward ethical concerns, and the agency will lose the credibility needed to negotiate nuanced, risk‑based policies for cutting‑edge work—think synthetic cells, gene‑edited organisms, or powerful AI models.

In short, politicizing grant review could cripple the soft‑power the NIH has quietly cultivated for decades. Without that leverage, the federal government may find itself staring down emerging scientific threats without a trusted conduit to the very people who understand them best.

The stakes are high, and the timeline is short. As the OMB scrambles to polish the final rule, the scientific community—and the public—should be asking not just how funding will be allocated, but whether we’re willing to sacrifice the NIH’s unique ability to keep dangerous science in check.